A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation

This is a single-arm, open-label clinical study to evaluate the safety, tolerability and preliminary efficacy of IX001 TCR-T injection in advanced pancreatic cancer patients with KRAS G12V mutation.

Trial Details

NCT ID
NCT06898385
Phase
PHASE1
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • IX001 TCR-T injection
  • Fludarabine
  • Cyclophosphamide
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • 1\. Voluntary signing of an informed consent form (for Human Leukocyte Antigen (HLA) typing and tumor gene mutation test, and main screening)
  • 2\. Males or females, aged 18-75 years (inclusive)
  • 3\. Patients with pathologically (histopathologically) or cytologically confirmed pancreatic ductal adenocarcinoma
  • 4\. Patients with unresectable locally advanced or metastatic disease who fail standard of care, i.e., patients who have progression after prior ge…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →